about
Followup of patients with interstitial cystitis responsive to treatment with intravesical bacillus Calmette-Guerin or placebo.Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study.Association of metabolic syndrome with development of new-onset diabetes after transplantation.Symptoms characteristic of heart failure among CKD patients without diagnosed heart failure.Metabolic syndrome, components, and cardiovascular disease prevalence in chronic kidney disease: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study.Race modifies the association between adiposity and inflammation in patients with chronic kidney disease: findings from the chronic renal insufficiency cohort study.Relationship of estimated GFR and coronary artery calcification in the CRIC (Chronic Renal Insufficiency Cohort) Study.Urinary sodium is a potent correlate of proteinuria: lessons from the chronic renal insufficiency cohort studyRelationship between adherence to hepatitis C virus therapy and virologic outcomes: a cohort study.Number, characteristics, and classification of patients with dermatomyositis seen by dermatology and rheumatology departments at a large tertiary medical center.Association of serum bicarbonate with risk of renal and cardiovascular outcomes in CKD: a report from the Chronic Renal Insufficiency Cohort (CRIC) study.Integrating acupuncture with exercise-based physical therapy for knee osteoarthritis: a randomized controlled trialAssociation of kidney disease outcomes with risk factors for CKD: findings from the Chronic Renal Insufficiency Cohort (CRIC) study.Sexual function is a determinant of poor quality of life for women with treatment refractory interstitial cystitis.Gender Differences in Achieving Optimal Lipid Goals in Patients With Coronary Artery DiseaseDid Patients With Interstitial Cystitis Who Failed to Respond to Initial Treatment With Bacillus Calmette-Guerin or Placebo in a Randomized Clinical Trial Benefit From a Second Course of Open Label Bacillus Calmette-Guerin?
P50
Q30439439-F1EFF187-8293-4126-A1AA-BD2230C609B3Q33837171-3C30EA0D-993D-49D4-8002-05B92F37BD73Q34222283-5B396DAF-C55C-4FFA-B597-97CEDC6F34E6Q34447671-97ECCAAF-5415-43E5-AF23-75A5545CFF9EQ34985147-EE5257F0-E63E-4D96-84CF-7F809F111478Q35082679-54614E38-BEDC-440E-88A4-4415FD5B2D83Q35242517-8B7E8FC0-BF19-498B-9AA0-5BD39C36D428Q35664862-75619A16-8A1D-486E-B36A-709104D5B4EDQ36006322-2675C4A7-F395-4AE5-8D9C-AB77ABD73836Q36965164-D7527370-31EA-462F-BA0A-EAAB18FB05D0Q36983156-D198A2EC-2322-4756-84A7-3B1A98954A94Q37195089-2FC243ED-ABF0-4EE2-9301-F32108F2DBBDQ37625225-E1CBDA36-BA95-40C2-893E-8103B2BD8CFFQ51904851-A2732330-A6AC-4E09-8BD9-2432B7EF110DQ62933446-BE30E42C-1C83-4DFC-B93C-E90F22848BF7Q62933592-55374A08-AC7B-437B-B714-83340AFACEF2
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Valerie Teal
@af
Valerie Teal
@an
Valerie Teal
@ast
Valerie Teal
@bar
Valerie Teal
@bm
Valerie Teal
@br
Valerie Teal
@ca
Valerie Teal
@co
Valerie Teal
@cs
Valerie Teal
@cy
type
label
Valerie Teal
@af
Valerie Teal
@an
Valerie Teal
@ast
Valerie Teal
@bar
Valerie Teal
@bm
Valerie Teal
@br
Valerie Teal
@ca
Valerie Teal
@co
Valerie Teal
@cs
Valerie Teal
@cy
prefLabel
Valerie Teal
@af
Valerie Teal
@an
Valerie Teal
@ast
Valerie Teal
@bar
Valerie Teal
@bm
Valerie Teal
@br
Valerie Teal
@ca
Valerie Teal
@co
Valerie Teal
@cs
Valerie Teal
@cy
P106
P21
P31
P496
0000-0001-7116-5353